Botox Side Effects and Risks: What the Label Says

A boxed warning is the strongest warning the FDA applies to a prescription product, and Botox Cosmetic carries one. It is short enough to read in full, and reading it in full matters, because the context the label supplies is routinely stripped out when the warning is quoted.

The warning states that postmarketing reports indicate the effects of Botox Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. It lists those symptoms as asthenia, generalized muscle weakness, double vision, drooping eyelid, difficulty swallowing, voice changes, slurred speech, urinary incontinence and breathing difficulties. It states these symptoms have been reported hours to weeks after injection, that swallowing and breathing difficulties can be life threatening, and that there have been reports of death.

Then it gives the context. The label says the risk of symptoms is probably greatest in children treated for spasticity, and that symptoms can also occur in adults treated for spasticity and other conditions, particularly those with an underlying condition that would predispose them. It also states that cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity, and at lower doses.

That last sentence is the one most often dropped when the warning gets quoted, and dropping it reverses its meaning. A labeled cosmetic treatment of the frown lines is 20 Units total, while doses used for cervical dystonia and spasticity run into the hundreds, so cosmetic dosing sits well below the therapeutic range. The label does not say that puts a cosmetic dose outside the warning. It says spread of effect has been reported at those therapeutic doses and at lower doses. What the label does identify as highest risk is children treated for spasticity, and adults with an underlying condition that would predispose them.

What that means practically: know the symptoms, and know they can appear weeks later. Difficulty swallowing, slurred speech, breathing trouble, generalized weakness or new double vision after any botulinum toxin injection is a reason to seek medical care immediately, not to wait and see.

The label's adverse reaction tables are the most concrete safety numbers available, because they come from randomized placebo controlled studies with a counted denominator. Botox Cosmetic is approved for four cosmetic areas: glabellar lines, lateral canthal lines, forehead lines and platysma bands. The label publishes reaction rates for three of them. For platysma bands it reports the trial sizes and states only that the safety profile is consistent with the known safety profile for the other indications, with no separate rate table. The table below is what the label publishes.

Read them for what they are. These are incidences within specific trials, not a general complication rate for cosmetic injecting, and the label itself notes that adverse reaction rates in trials cannot be directly compared across drugs or assumed to match what happens in practice.

The pattern across the three areas with published rates is that the reported reactions are local, closely related to the drug doing what it does. Eyelid ptosis and brow ptosis are the muscle relaxing effect reaching a muscle you did not want relaxed, which is why placement and dose matter more than almost anything else.

Botox Cosmetic is a sterile, vacuum dried purified botulinum toxin type A, produced from fermentation of the Hall strain of Clostridium botulinum type A. That is the label's own description, and it is the honest answer to the question people are really asking, which is whether they are being injected with a bacterial toxin. They are, in a purified and quantified form.

A vial contains very little else. Each vial holds either 50 or 100 Units of Clostridium botulinum type A neurotoxin complex, plus 0.25 or 0.5 mg of human albumin and 0.45 or 0.9 mg of sodium chloride, vacuum dried without a preservative. The practice reconstitutes that powder with sterile saline before injecting.

The albumin is a blood derivative, and the label addresses it directly. It states that based on effective donor screening and product manufacturing processes the product carries a remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease, that the risk of classic CJD transmission is theoretical and also remote, and that no cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

Mechanically, the toxin blocks neuromuscular transmission by binding to acceptor sites on motor nerve terminals and inhibiting the release of acetylcholine, cleaving a protein called SNAP-25 in the process. The label describes the result as partial chemical denervation of the injected muscle, producing a localized reduction in muscle activity, and it wears off as the nerve recovers. The label also notes that at recommended doses, current analytical technology cannot detect Botox Cosmetic in peripheral blood after intramuscular injection.

There is no published evidence that botulinum toxin injection causes cancer, and there is also no long term study that would settle the question. Both halves of that sentence are true, and leaving either one out would misrepresent the record.

The label states it plainly in its nonclinical toxicology section: long term studies in animals have not been performed to evaluate carcinogenic potential of Botox Cosmetic. That is not a finding of safety. It is an absence of the study type that regulators use to assess carcinogenic potential.

What has been done is genotoxicity testing, which looks for the kind of DNA damage that can initiate cancer. The label reports that Botox Cosmetic was negative in a battery of in vitro assays, specifically a microbial reverse mutation assay, a mammalian cell mutation assay and a chromosomal aberration assay, and in an in vivo micronucleus assay. A negative genotoxicity battery is meaningful but limited: it tests a mechanism, not an outcome in people.

On the human side, searches of the biomedical literature for this guide did not locate an epidemiological study measuring cancer incidence among people who have received cosmetic botulinum toxin. The product has been used cosmetically since FDA approval in 2002, and no study has been designed to look for such a signal.

So the accurate position is narrow. Nothing published links botulinum toxin to cancer, the mechanistic testing that exists came back negative, and the long term carcinogenicity work has not been done. If a source tells you cancer risk has been ruled out, ask what study they are citing.

In April 2024 both the FDA and the CDC issued warnings after people were hospitalized with botulism like illness following cosmetic injections. Those cases were not about approved product used correctly, and understanding the distinction is the single most useful safety lesson available.

The FDA's notice, issued April 16 and updated May 1, 2024, stated that unsafe counterfeit versions of Botox had been found in multiple states. Reported symptoms included blurred or double vision, difficulty swallowing, dry mouth, constipation, incontinence, shortness of breath, weakness and difficulty lifting one's head. The FDA stated that the incidents occurred when counterfeit Botox was injected by licensed and unlicensed individuals and in non medical or unlicensed settings, and that there was no indication the reported events were linked to the FDA approved product.

The CDC issued Health Alert Network advisory HAN-00507 on April 23, 2024, titled Adverse Effects Linked to Counterfeit or Mishandled Botulinum Toxin Injections. Its final investigation update, dated June 24, 2024, recorded 17 people across 9 states reporting harmful reactions between November 4, 2023 and April 11, 2024. Thirteen of them, 76 percent, were hospitalized, and 6, or 35 percent, were treated with botulism antitoxin. The affected states were California, Colorado, Florida, Illinois, Kentucky, New Jersey, New York, Tennessee and Texas.

A separate CDC field report covering Tennessee and New York City described seven women who became ill after injections in nonmedical settings, with symptom onset between February 23 and March 7, 2024. Four were hospitalized, two were monitored in intensive care, and reported signs included drooping eyelid, dry mouth, difficulty swallowing, shortness of breath and weakness.

The common thread in all of it is sourcing and setting rather than the molecule. Product bought outside authorized distribution, injected by people not following the requirements of their state, in places that are not clinical environments. Those are answerable questions before you book.

The outcomes people describe as Botox gone wrong are overwhelmingly placement and dosing problems in the upper face, not systemic events. In the labeled forehead trials, brow ptosis was reported in 2 percent of treated subjects and eyelid ptosis in 2 percent, against essentially none on placebo.

Brow ptosis has a mechanical explanation. The frontalis is the only muscle that lifts the brow, so relaxing it without accounting for the muscles that pull the brow down can leave the brow sitting lower than it started. Treating the frown lines in the same session is not injector custom: the label's own forehead lines dosing is 4 Units into each of 5 forehead sites, 20 Units, together with 4 Units into each of 5 glabellar line sites, 20 Units, for a recommended total of 40 Units. The forehead trials were run that way, which is why the table above reads forehead lines with glabellar.

Eyelid ptosis, a drooping upper lid, comes from product reaching the levator muscle that holds the lid up. It is reported in 3 percent of glabellar line subjects and 2 percent of forehead line subjects in the label's trials. It resolves as the product wears off. The label describes no treatment for it, and nothing reverses the cosmetic effect once the product is placed, so ask your injector what to expect and over what period.

Asymmetry, an unnaturally flat or heavy look, and a frozen expression are dose and placement outcomes rather than named adverse drug reactions. The label's nearest terms are narrower and it does count them: facial paresis in 1 percent of glabellar line subjects, muscular weakness in 1 percent, and brow ptosis in 2 percent of forehead line subjects. What the label does not have is a category for a result you simply do not like. Nothing reverses a neuromodulator's cosmetic effect, so the remedy in all of these cases is time. Botulism antitoxin is a different thing entirely: it treats systemic botulism, it is given in hospital, and the CDC reported it was used in 6 of the 17 counterfeit product cases described in the previous section. It does nothing for a cosmetic result. That is exactly why experienced injectors start conservatively with a new patient and adjust at a two week follow up.

The label separately warns about unapproved uses. It reports that serious adverse reactions, including excessive weakness, difficulty swallowing and aspiration pneumonia, some with fatal outcomes, have been reported in patients who received Botox injections for unapproved uses, and that safety and effectiveness for unapproved uses have not been established. Off label cosmetic use is common and legal, but it is worth knowing which category your treatment falls into.

The label lists two contraindications: known hypersensitivity to any botulinum toxin product or to any component in the formulation, and infection at the proposed injection site. Both are absolute.

Beyond that, the label flags conditions that raise the risk of a clinically significant effect. Pre existing neuromuscular disorders are singled out, as are compromised respiratory function and existing swallowing difficulty. If any of that applies to you, it belongs in the conversation before a dose is chosen, not after.

Postmarketing reports in the label include spontaneous reports of death, sometimes associated with difficulty swallowing, pneumonia, other significant debility or anaphylaxis, and reports of cardiovascular events including arrhythmia and myocardial infarction, some with fatal outcomes, in patients who in some cases had cardiovascular risk factors. The label is explicit that because these are voluntary reports from a population of uncertain size, their frequency cannot be reliably estimated and causation cannot be established.

Tell your provider about every medication you take. The label warns that co-administration with aminoglycosides or other agents interfering with neuromuscular transmission should only be done with caution because the effect of the toxin may be potentiated, and that excessive weakness may be exaggerated by a muscle relaxant given before or after Botox Cosmetic.

And ask directly about sourcing and oversight: which product, which authorized distributor, who is injecting, what license they hold, and who the supervising physician is. Those questions are not adversarial. They are the same questions the 2024 investigations turned on.